GRID Therapy for Tumors of the Head, Neck, Thorax, Abdomen, Pelvis and Extremities. (ROR1903)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study is an observational registry study evaluating the clinical outcomes of grid therapy. Subjects will be screened at outpatient clinic visit appointments and interested qualified subjects will be consented and offered participation in this study. Once consent has been obtained, baseline adverse event and QOL data will be collected and subjects will undergo grid therapy and follow-up at 2-4 weeks (for toxicity), and 3-6 months (for toxicities and radiographic control) then per clinical discretion up to 1 year. Patients will be evaluated according to the physician's standard practice and discretion. Patient data will be drawn from the patients' medical records and reported by means of a web-based electronic data collection (EDC) system. Patients will be considered "on study" until 60 months of observation has occurred, withdrawal of consent, lost to follow-up, or study closure. See below for the clinical visit flowchart for data collected at baseline and standard clinic visits.
Grid therapy allows for high doses of radiation to be delivered over several spatially distinct, small regions. This permits regions of very high dose to a large tumor away from critical structures, which could be beneficial in both palliative and definitive treatments. Additionally, allowing for high doses to be delivered could pose a benefit for radioresistant histologies.
To describe the local/radiographic control rate (per RECIST) in patients treated with GRID therapy. [ Time Frame: 3-6 months ]
Secondary Outcome Measures :
To describe the adverse event profile (acute and late) of grid therapy by assessment of grade 3 or higher adverse events NCI-CTCAE v. 5 criteria. [ Time Frame: through study completion, approximately 5 years ]
Overall survival [ Time Frame: through study completion, approximately 5 years ]
Patient survival rate after grid therapy
Local/regional progression [ Time Frame: through study completion, approximately 5 years ]
Patient progression after grid therapy
Recurrence rate [ Time Frame: through study completion, approximately 5 years ]
Number of patients to have tumor recurrence after grid therapy
Distant disease control [ Time Frame: through study completion, approximately 5 years ]
Planning and delivery of grid therapy. [ Time Frame: 5 years ]
Total amount of time taken for planning and delivery of grid therapy
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients with tumors of the head, neck, thorax, abdomen, pelvis and extremities.
Patients with tumors of the head and neck, thorax, abdomen, pelvis, and extremities.
Age ≥ 18 years.
Histological confirmation of oncologic diagnosis.
Completed oncologic imaging (per discretion of treating physician)
ECOG Performance Status 0-3
Ability to complete questionnaire(s) by themselves or with assistance.
Willing to return to enrolling institution for follow-up (during the Active Monitoring Phase of the study).
Provide informed written consent.
Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:
Women of childbearing potential who are unwilling to employ adequate contraception
Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
Immunocompromised patients and patients known to be HIV positive and currently receiving antiretroviral therapy. NOTE: Patients known to be HIV positive, but without clinical evidence of an immunocompromised state, are eligible for this trial.
Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.